3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

F Cardoso; A Costa; E Senkus; M Aapro; F André; C H Barrios; J Bergh; G Bhattacharyya; L Biganzoli; M J Cardoso; L Carey; D Corneliussen-James; G Curigliano; V Dieras; N El Saghir; A Eniu; L Fallowfield; D Fenech; P Francis; K Gelmon; A Gennari; N Harbeck; C Hudis; B Kaufman; I Krop; M Mayer; H Meijer; S Mertz; S Ohno; O Pagani; E Papadopoulos; F Peccatori; F Penault-Llorca; M J Piccart; J Y Pierga; H Rugo; L Shockney; G Sledge; S Swain; C Thomssen; A Tutt; D Vorobiof; B Xu; L Norton; E Winer

doi:10.1016/j.breast.2016.10.001

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

Breast. 2017 Feb:31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5.

Authors

F Cardoso¹, A Costa², E Senkus³, M Aapro⁴, F André⁵, C H Barrios⁶, J Bergh⁷, G Bhattacharyya⁸, L Biganzoli⁹, M J Cardoso¹⁰, L Carey¹¹, D Corneliussen-James¹², G Curigliano¹³, V Dieras¹⁴, N El Saghir¹⁵, A Eniu¹⁶, L Fallowfield¹⁷, D Fenech¹⁸, P Francis¹⁹, K Gelmon²⁰, A Gennari²¹, N Harbeck²², C Hudis²³, B Kaufman²⁴, I Krop²⁵, M Mayer²⁶, H Meijer²⁷, S Mertz²⁸, S Ohno²⁹, O Pagani³⁰, E Papadopoulos³¹, F Peccatori², F Penault-Llorca³², M J Piccart³³, J Y Pierga³⁴, H Rugo³⁵, L Shockney³⁶, G Sledge³⁷, S Swain³⁸, C Thomssen³⁹, A Tutt⁴⁰, D Vorobiof⁴¹, B Xu⁴², L Norton⁴³, E Winer²⁵

Affiliations

¹ European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt.
² European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland.
³ Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
⁴ Breast Center, Genolier Cancer Center, Genolier, Switzerland.
⁵ Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France.
⁶ Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil.
⁷ Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden.
⁸ Department of Medical Oncology, Fortis Hospital, Kolkata, India.
⁹ Medical Oncology Department, Hospital of Prato, Prato, Italy.
¹⁰ Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal.
¹¹ Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, USA.
¹² METAvivor Research and Support, Annapolis, USA.
¹³ Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy.
¹⁴ Department of Medical Oncology, Institut Curie, Paris, France.
¹⁵ NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut, Beirut, Lebanon.
¹⁶ Department of Breast Tumors, Cancer Institute 'I. Chiricuta', Cluj-Napoca, Romania.
¹⁷ Brighton & Sussex Medical School, University of Sussex, Falmer, UK.
¹⁸ Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta.
¹⁹ Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
²⁰ BC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada.
²¹ Department of Medical Oncology, Galliera Hospital, Genoa, Italy.
²² Brustzentrum der Universitat München, Munich, Germany.
²³ Breast Medicine Service, Memorial Sloan-Kettering Cancer Centre, New York, USA.
²⁴ Sheba Medical Center, Tel Hashomer, Israel.
²⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
²⁶ Advanced BC.org, New York, USA.
²⁷ Department of Radiation Oncology, Radvoud University Medical Center, Nijmegen, The Netherlands.
²⁸ Metastatic Breast Cancer Network US, Inversness, USA.
²⁹ Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan.
³⁰ Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland.
³¹ Europa Donna, Nicosia, Cyprus.
³² Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France.
³³ Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
³⁴ Department of Medical Oncology, Institut Curie-Université Paris Descartes, Paris, France.
³⁵ Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
³⁶ Department of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore, USA.
³⁷ Indiana University Medical CTR, Indianapolis, USA.
³⁸ Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA.
³⁹ Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, DE, Germany.
⁴⁰ Breakthrough Breast Cancer Research Unit, King's College London and Guy's and St Thomas's NHS Foundation Trust, London, UK.
⁴¹ Sandton Oncology Centre, Johannesburg, South Africa.
⁴² Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
⁴³ Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA.

PMID: 27927580
DOI: 10.1016/j.breast.2016.10.001

No abstract available

Publication types

Practice Guideline

MeSH terms

Antineoplastic Agents / therapeutic use
Breast Neoplasms / chemistry
Breast Neoplasms / pathology*
Breast Neoplasms / therapy*
Consensus Development Conferences as Topic
Female
Humans
Palliative Care*
Receptor, ErbB-2 / analysis*
Receptors, Estrogen / analysis*
Triple Negative Breast Neoplasms / drug therapy

Substances

Antineoplastic Agents
Receptors, Estrogen
ERBB2 protein, human
Receptor, ErbB-2